This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis' Alexander Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis
by Zacks Equity Research
Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.
Akcea Therapeutics (AKCA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.
BioNTech (BNTX) Looks Good: Stock Adds 5.9% in Session
by Zacks Equity Research
BioNTech (BNTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Evofem Biosciences (EVFM) Looks Good: Stock Adds 10.1% in Session
by Zacks Equity Research
Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Kamada (KMDA) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Retrophin (RTRX) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Neoleukin Therapeutics (NLTX) Looks Good: Stock Adds 9.4% in Session
by Zacks Equity Research
Neoleukin Therapeutics (NLTX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up
by Zacks Equity Research
Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
Zymeworks (ZYME) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Agenus Stock Up on Licensing Deal With China-Based Firm
by Zacks Equity Research
Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
Osmotica Pharmaceuticals (OSMT) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Dynavax Technologies (DVAX) Jumps: Stock Rises 6.6%
by Zacks Equity Research
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Incyte (INCY) Looks Good: Stock Adds 8.3% in Session
by Zacks Equity Research
Incyte (INCY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
All You Need to Know About Akcea Therapeutics (AKCA) Rating Upgrade to Strong Buy
by Zacks Equity Research
Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.